Abstract: Valemetostat (DS-3201, EZHARMIA) is a novel, orally bioavailable, and highly selective dual inhibitor of the enhancer of zeste homolog 1 and 2 (EZH1/2) proteins, which are critical catalytic subunits of the polycomb repressive complex 2 (PRC2). While initially approved for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma (R/R ATL), valemetostat is increasingly being investigated for its therapeutic potential in solid tumors. The overexpression or mutation of EZH2 is implicated in the progression and poor prognosis of various solid malignancies, including non-small cell lung cancer, prostate cancer, and breast cancer. By competitively inhibiting both EZH1 and EZH2, valemetostat effectively reduces global histone H3 lysine 27 tri-methylation (H3K27me3) levels, reactivates silenced tumor suppressor genes, and overcomes the compensatory EZH1 activity that often limits selective EZH2 inhibitors. This review synthesizes current literature on the pharmacological activity, molecular mechanism, structure-activity relationship, limitations, and future perspectives of valemetostat, with a specific focus on its emerging role in the treatment of solid tumors.
1. Introduction
Epigenetic regulators of gene expression have emerged as a prominent target class for cancer therapy. The polycomb repressive complex 2 (PRC2) plays a fundamental role in regulating chromatin structure and gene expression, primarily through the tri-methylation of the 27th lysine residue of histone H3 (H3K27me3) [1]. Enhancer of zeste homolog 2 (EZH2) and its homolog EZH1 serve as the catalytic subunits of PRC2. The hyperactivation, overexpression, or gain-of-function mutations of EZH2 are frequently observed in a wide array of solid tumors, including non-small cell lung carcinoma (NSCLC), colorectal cancer, aggressive breast cancer, pancreatic cancer, and hormone-refractory prostate cancer [2]. This dysregulation leads to the inappropriate silencing of tumor suppressor genes and is closely correlated with tumor aggressiveness, metastasis, and poor patient prognosis [2].
Valemetostat tosilate (DS-3201b; EZHARMIA) is an orally administered, potent, and selective dual inhibitor of both wild-type and mutated forms of EZH1 and EZH2 developed by Daiichi Sankyo [1]. While it received its first global approval in Japan in September 2022 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma (R/R ATL) [1], its unique dual-inhibition profile has prompted extensive clinical investigation into its efficacy against various solid tumors [2].
2. Pharmacological Activity
Valemetostat has demonstrated significant antiproliferative activity across multiple cancer models. In the context of solid tumors, valemetostat is currently being evaluated in several clinical trials to establish its safety, tolerability, and efficacy. Ongoing phase 1 and phase 2 clinical studies are investigating valemetostat both as a monotherapy and in combination regimens for various solid malignancies [1] [2].
Key clinical trials targeting solid tumors include a US phase 1/2 trial (NCT03879798) evaluating valemetostat in combination with irinotecan for patients with recurrent small cell lung cancer (SCLC) [1]. Another US phase 1 trial (NCT04388852) is assessing the drug in combination with the immune checkpoint inhibitor ipilimumab for patients with metastatic prostate, urothelial, and renal cell cancers [1]. Furthermore, a Japanese phase 1 trial (jRCT2031190268; ELEPHANT) is investigating valemetostat monotherapy in pediatric, adolescent, and young adult patients (aged 3 to 29 years) with malignant solid tumors [1]. Additional proposed or recruiting studies are exploring its efficacy in HER2 low/ultra-low/null metastatic breast cancer, HPV-negative head and neck squamous cell carcinoma (HNSCC), sinonasal carcinoma, and squamous NSCLC, often in conjunction with other targeted agents or immunotherapies like atezolizumab and bevacizumab [2].
3. Molecular Mechanism of Action
The primary mechanism of action of valemetostat involves the competitive inhibition of the S-adenosylmethionine (SAM) binding pocket of both EZH1 and EZH2 methyltransferases [2]. In cell-free enzymatic assays, valemetostat exhibits high potency, with an IC50 of 10.0 nM for EZH1 and 6.0 nM for EZH2 [1]. By inhibiting these catalytic subunits of PRC2, valemetostat prevents the tri-methylation of histone H3 at lysine 27 (H3K27me3) [1].
The dual inhibition of EZH1 and EZH2 is a critical mechanistic advantage. Preclinical studies have shown that when cells are exposed to selective EZH2 inhibitors (such as tazemetostat), EZH1 can compensate for the loss of EZH2 activity, leading to ectopic EZH1 accumulation and a partial restoration of H3K27me3 levels, which maintains the silencing of tumor suppressor genes [1]. In contrast, valemetostat's dual inhibition prevents this compensatory mechanism. Treatment with valemetostat significantly and persistently reduces global H3K27me3 levels without ectopic enrichment of EZH1/2, thereby successfully reactivating silenced gene expression, altering cancer pathway transcription, and inducing cell differentiation and apoptosis in malignant cells [1] [2].
4. Structure-Activity Relationship (SAR)
Valemetostat tosilate is a small molecule characterized chemically as an amide and benzodioxole derivative. Its IUPAC name is (2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide mono(4-methylbenzenesulfonate) [1]. Structurally, it is designed to act as a SAM-competitive inhibitor, binding to the active site of the EZH1 and EZH2 enzymes to block the transfer of methyl groups [2].
The structural optimization of valemetostat confers excellent oral bioavailability and potent dual-targeting capabilities. This dual-targeting structure is vital for its activity profile; by effectively binding both EZH1 and EZH2, the molecule overcomes the structural and functional redundancies of the PRC2 complex. This provides greater efficacy against potential drug resistance that typically arises with highly selective EZH2 inhibitors, making it a robust pharmacological agent against heterogeneous tumor profiles [2].
5. Current Limitations
Despite its therapeutic promise, the clinical application of valemetostat is accompanied by several limitations, primarily related to adverse events and pharmacokinetic interactions. The most frequent adverse reactions observed in clinical trials include hematological toxicities such as thrombocytopenia, anemia, leukopenia, lymphopenia, and neutropenia [1] [2]. Non-hematological adverse events include alopecia, dysgeusia, dry skin, rash, nausea, fatigue, and elevated liver transaminases (ALT/AST) [1]. Severe myelosuppression requires careful patient monitoring and may necessitate dose interruptions or reductions [1].
Pharmacokinetically, valemetostat is predominantly metabolized by the CYP3A enzyme and is both a substrate and inhibitor of the P-glycoprotein (P-gp) efflux pump [1]. Co-administration with strong CYP3A or P-gp inhibitors (e.g., itraconazole) significantly increases valemetostat exposure, requiring strict dose reductions to avoid severe toxicity. Conversely, strong CYP3A inducers (e.g., rifampicin) decrease its exposure, potentially reducing therapeutic efficacy [1]. Furthermore, food significantly impacts its absorption, reducing maximum concentration (Cmax) and area under the curve (AUC), meaning the drug must be administered on an empty stomach [1]. Finally, while dual inhibition mitigates some resistance, the activation of alternative signaling pathways (such as IGF-1R, PI3K, and MEK) has been identified as a potential mechanism of resistance to SAM-competitive EZH2 inhibitors, which may also impact valemetostat's long-term efficacy [2].
6. Future Perspectives
The future development of valemetostat in solid tumors relies heavily on combination strategies and precision medicine. Because EZH2 modulates the tumor microenvironment—often suppressing immune cell infiltration and function—combining valemetostat with immune checkpoint inhibitors (such as ipilimumab or pembrolizumab) holds significant promise for enhancing anti-tumor immunity in solid malignancies like prostate and urothelial cancers [1] [2]. Additionally, synergistic combinations with standard cytotoxic chemotherapies, such as irinotecan in SCLC, are actively being explored to overcome resistance and improve response rates [1].
Future research must also focus on identifying robust predictive biomarkers to stratify patients who will derive the greatest benefit from dual EZH1/2 inhibition. Investigating specific genetic alterations, such as EZH2 mutations, SWI/SNF complex deficiencies, or specific pathway dependencies, will be crucial for optimizing patient selection [2]. As clinical data from ongoing solid tumor trials mature, the therapeutic niche of valemetostat will become clearer, potentially establishing it as a cornerstone epigenetic therapy beyond hematological malignancies.
